Compare AMCI & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCI | FLNA |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 30.0M |
| IPO Year | 2022 | 2000 |
| Metric | AMCI | FLNA |
|---|---|---|
| Price | $0.82 | $0.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 130.9K | ★ 462.6K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,980,847.00 | ★ $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.39 |
| 52 Week High | $15.75 | $2.03 |
| Indicator | AMCI | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 27.43 | 48.13 |
| Support Level | N/A | $0.43 |
| Resistance Level | $3.99 | $0.68 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.16 | 73.00 |
AMC Robotics Corp is a technology solutions company that offers AI-powered smart security and robotics solutions. It currently sells smart hardware products designed for residential and commercial use, including smart cameras, driving recorders, action cameras, and Retina K cameras, which are marketed under the YI brand. AMC Robotics is also engaged in developing additional hardware products and technology capabilities, including IoT-enabled devices, AI-based features, wearable devices, and AI robotics. Using its technological capabilities, the company is developing robotic dogs, robotic arms, and robotic unloading systems, offering smart solutions for the logistics and warehousing sectors. It has two primary operating segments: North America, which generates maximum revenue, and Europe.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.